A Preclinical Evaluation of Antimycin A as a Potential Antilung Cancer Stem Cell Agent
المؤلفون المشاركون
Huang, Chi-Ying F.
Wu, Chih-Hsiung
Lee, Wei-Hwa
Yeh, Chi-Tai
Jan, Yi-Hua
Wang, Liang-Shun
Shieh, Yi-Shing
Wu, Alexander T. H.
Lin, Justin Kung-Yi
Chang, Peter Mu-Hsin
Hsiao, Michael
Liu, Yu-Wen
Chuang, Yung-Jen
Kuo, Yu-Lun
Su, Chun-Li
المصدر
Evidence-Based Complementary and Alternative Medicine
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-06-11
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
Drug resistance and tumor recurrence are major obstacles in treating lung cancer patients.
Accumulating evidence considers lung cancer stem cells (CSCs) as the major contributor to these clinical challenges.
Agents that can target lung CSCs could potentially provide a more effective treatment than traditional chemotherapy.
Here, we utilized the side-population (SP) method to isolate lung CSCs from A549 and PC-9 cell lines.
Subsequently, a high throughput platform, connectivity maps (CMAPs), was used to identify potential anti-CSC agents.
An antibiotic, antimycin A (AMA), was identified as a top candidate.
SP A549 cells exhibited an elevated stemness profile, including Nanog, β-catenin, Sox2, and CD133, and increased self-renewal ability.
AMA treatment was found to suppress β-catenin signaling components and tumor sphere formation.
Furthermore, AMA treatment decreased the proliferation of gefitinib-resistant PC-9/GR cells and percentage of SP population.
AMA demonstrated synergistic suppression of PC-9/GR cell viability when combined with gefitinib.
Finally, AMA treatment suppressed tumorigenesis in mice inoculated with A549 SP cells.
Collectively, we have identified AMA using CMAP as a novel antilung CSC agent, which acts to downregulate β-catenin signaling.
The combination of AMA and targeted therapeutic agents could be considered for overcoming drug resistance and relapse in lung cancer patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Yeh, Chi-Tai& Su, Chun-Li& Huang, Chi-Ying F.& Lin, Justin Kung-Yi& Lee, Wei-Hwa& Chang, Peter Mu-Hsin…[et al.]. 2013. A Preclinical Evaluation of Antimycin A as a Potential Antilung Cancer Stem Cell Agent. Evidence-Based Complementary and Alternative Medicine،Vol. 2013, no. 2013, pp.1-13.
https://search.emarefa.net/detail/BIM-507396
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yeh, Chi-Tai…[et al.]. A Preclinical Evaluation of Antimycin A as a Potential Antilung Cancer Stem Cell Agent. Evidence-Based Complementary and Alternative Medicine No. 2013 (2013), pp.1-13.
https://search.emarefa.net/detail/BIM-507396
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Yeh, Chi-Tai& Su, Chun-Li& Huang, Chi-Ying F.& Lin, Justin Kung-Yi& Lee, Wei-Hwa& Chang, Peter Mu-Hsin…[et al.]. A Preclinical Evaluation of Antimycin A as a Potential Antilung Cancer Stem Cell Agent. Evidence-Based Complementary and Alternative Medicine. 2013. Vol. 2013, no. 2013, pp.1-13.
https://search.emarefa.net/detail/BIM-507396
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-507396
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر